Placebo Impacts Sleep and Pain Modulation in Chronic Pain
Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Jan 16, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how an open-label placebo (OLP) might help improve sleep and reduce pain in people with temporomandibular disorders (TMD), which are painful conditions affecting the jaw. In this study, participants will be divided into three groups: one will take an OLP along with a session to discuss their expectations about the treatment; another group will take the OLP without any additional discussion; and the third group will continue with their usual care without the placebo. Researchers want to see if taking the OLP helps reduce pain, anxiety, and depression, and improves sleep quality for those suffering from TMD.
To participate, individuals must be between 18 and 88 years old, speak English, and have had TMD for at least three months. Participants will need to have a smartphone for communication and should be able to record their pain and sleep patterns during the study. It's important to note that people with certain health conditions or psychiatric histories will not be eligible for this trial. Over the course of 45 days, participants will report on their pain levels and sleep quality, helping researchers understand the potential benefits of the open-label placebo approach.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ( 18-88 years old)
- • English speaker (written and spoken)
- • TMD for at least 3 months
- • Grade Chronic Pain Scale (GCPS) ≥1
- • Smartphone/text messaging capability
- Exclusion Criteria:
- • Present or past degenerative neuromuscular disease
- • Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years
- • Any personal (or family first degree) history of mania, schizophrenia, or other psychoses
- • Severe psychiatric condition (e.g. schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.
- • Lifetime alcohol/drug dependence or alcohol/drug abuse in past 3 months
- • Pregnancy or breast feeding
- • Impaired or uncorrected hearing
About University Of Maryland, Baltimore
The University of Maryland, Baltimore (UMB) is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, UMB leverages its extensive resources and expertise across various disciplines, including medicine, pharmacy, nursing, and social work, to contribute to groundbreaking discoveries and improve patient outcomes. Committed to ethical research practices and collaboration, UMB fosters an environment that promotes the translation of scientific knowledge into real-world applications, ultimately enhancing the well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported